Analysts on Wall Street project that Abbott (ABT) will announce quarterly earnings of $1.42 per share in its forthcoming report, representing an increase of 9.2% year over year. Revenues are projected to reach $12.97 billion, increasing 14.1% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net sales- Nutrition' of $2.21 billion. The estimate suggests a change of +2.7% year over year.
Analysts' assessment points toward 'Net sales- Diagnostics' reaching $3.29 billion. The estimate indicates a year-over-year change of +45.9%.
Based on the collective assessment of analysts, 'Net sales- Medical Devices- Diabetes Care' should arrive at $2.20 billion. The estimate indicates a year-over-year change of +6.8%.
According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.61 billion. The estimate points to a change of +6.8% from the year-ago quarter.
Analysts predict that the 'Net sales- Nutrition- U.S.' will reach $931.65 million. The estimate indicates a change of +4.9% from the prior-year quarter.
It is projected by analysts that the 'Net sales- Nutrition- International' will reach $1.28 billion. The estimate suggests a change of +1.3% year over year.
The combined assessment of analysts suggests that 'Net sales- Diagnostics- U.S.' will likely reach $1.85 billion. The estimate indicates a change of +108.3% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Diagnostics- International' will reach $1.44 billion. The estimate suggests a change of +5.7% year over year.
Analysts expect 'Net sales- Medical Devices- Neuromodulation- International' to come in at $63.91 million. The estimate indicates a year-over-year change of +10.2%.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $388.69 million. The estimate indicates a year-over-year change of +11.1%.
The consensus estimate for 'Net sales- Medical Devices- Rhythm Management- International' stands at $350.76 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Analysts forecast 'Net sales- Medical Devices- Structural Heart- U.S.' to reach $245.18 million. The estimate indicates a change of -17.5% from the prior-year quarter.
View all Key Company Metrics for Abbott here>>>Abbott shares have witnessed a change of +2.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).